Derma Sciences (DSCI) Reports In-Line Q3 EPS

Derma Sciences (NASDAQ: DSCI) reported Q3 EPS of ($0.04), in-line with the analyst estimate of ($0.04). Revenue for the quarter came in at $21.8 million versus the consensus estimate of $23.9 million.

GUIDANCE:

Derma Sciences sees FY2016 revenue of $81.6 million, versus the consensus of $92.4 million.

For earnings history and earnings-related data on Derma Sciences (DSCI) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• CaliberCos Inc (CWD) Misses Q2 EPS by 43c; Offers Guidance
• Star Equity Holdings (STRR) Misses Q2 EPS by 8c